lated that the specificity of drug activity toward viruses may be reflected by the development of mutant viruses resistant to the drugs. Thus, drug inhibitory effects against cell mechanisms would be differentiated from those specific for viral replicative mechanisms.
In earlier work Huffman et al. (3) demonstrated that type 1 herpesvirus (HV/1) did not develop resistance to ribavirin after four passages in KB cells or five passages in Vero cells, whereas in parallel experiments it readily developed resistance to idoxuridine (IDU). Furthermore, it seemed that IDU stimulated cross-resistance to ribavirin in KB cells; however, this possibility had not been explored in Vero cells. This suggested that IDU might act as a mutagen that enhanced or stimulated the production of virus resistant to ribavirin. Also, the HV/1 resistant to IDU that was developed in Vero cells showed increased plaque formation in the presence of ribavirin (cross-resistance).
After reevaluation of this earlier work, we repeated the HV/1-Vero cell study and carried the virus through 10 passages in the presence of drug-free medium, 10 ,ug of ribavirin per ml or 10 Ag of IDU per ml, which represented approximately equipotent concentrations of each. This greater number of passages was expected to increase the opportunity for drug-induced resistance or cross-resistance.
In these experiments, Vero (African green monkey kidney) cells suspended in minimal essential medium plus 10% fetal bovine serum (Irvine Scientific Co., Fountain Valley, Calif.) and 0.1% NaHC03 were placed in Multi-dishes (Linbrow Scientific Co., Inc., New Haven, Conn.). The cells were allowed to grow to confluency at 370C in a moist 5% C02-95% air atmosphere environment. For virus passage and evaluation of resistance, a mixture of minimal essential medium plus 5% fetal bovine serum, 0.25% NaHCO3, and 50 ,g of gentamicin per ml was used as the test or maintenance medium.
The virus pools were prepared by the dilution of the virus in the test medium and adsorption to cells for 1 h, followed by the addition of 3 ml of drug-free medium or medium containing 10 pkg of ribavirin or IDU per ml. The cells were then returned to the incubator until virus cytopathic effect developed in cells without the drug. The dishes were then frozen and thawed one time, cell debris was separated from the medium by centrifugation, the supernatant fluid was ampouled and sealed, and pools were quickly frozen. This procedure was repeated until the viruses had been passaged 10 times.
Susceptibility or resistances of the viruses to ribavirin or IDU were determined by plaque techniques. To ensure that the separate virus pools contained essentially equal concentrations ofchallenge virus in plaque-forming units in antiviral experiments, the pools were pretitered by adsorbing (1 h) them on replicate monolayers with 0.1 ml of serial log,0 dilutions of virus in the maintenance medium. The cells were then overlaid with a 4-ml mixture ofequal volumes of 1.8% Seakem agarose (MCI Biomedical, Division of Marine Colloids, Inc., Rockland, Maine) and 2x maintenance medium.
After 3 days of incubation at 370C in the moist C02 environment, 1 ml of 1:5,000 neutral red in saline was added for 1.5 h. The excess neutral red was then removed, and cells were incubated for an additional 6 h prior to plaque counting.
After determining dilutions for obtaining comnparable plaque-forming units, the viruses were tested in medium containing 10, 100, or 1,000 gg of ribavirin (Fig. 1) or IDU (Fig. 2) 
